Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2016

01-02-2016 | Endocrine Tumors

Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer

Authors: Iain J. Nixon, PhD, Deborah Kuk, ScM, Volkert Wreesmann, PhD, Luc Morris, MD, Frank L. Palmer, BA, Ian Ganly, PhD, Snehal G. Patel, MD, Bhuvanesh Singh, MD, R. Michael Tuttle, MD, Ashok R. Shaha, MD, Mithat Gönen, PhD, Jatin P. Shah, PhD

Published in: Annals of Surgical Oncology | Issue 2/2016

Login to get access

Abstract

Background

Age 45 years is used as a cutoff in the staging of well-differentiated thyroid cancer (WDTC) as it represents the median age of most datasets. The aim of this study was to determine a statistically optimized age threshold using a large dataset of patients treated at a comprehensive cancer center.

Methods

Overall, 1807 patients with a median follow-up of 109 months were included in the study. Recursive partitioning was used to determine which American Joint Committee on Cancer (AJCC) variables were most predictive of disease-specific death, and whether a different cutoff for age would be found. From the resulting tree, a new age cutoff was picked and patients were restaged using this new cutoff.

Results

The 10-year disease-specific survival (DSS) by Union for International Cancer Control (AJCC/UICC) stage was 99.6, 100, 96, and 81 % for stages I–IV, respectively. Using recursive partitioning, the presence of distant metastasis was the most powerful predictor of DSS. For M0 patients, age was the next most powerful predictor, with a cutoff of 56 years. For M1 patients, a cutoff at 54 years was most predictive. Having reviewed the analysis, age 55 years was selected as a more robust age cutoff than 45 years. The 10-year DSS by new stage (using age 55 years as the cutoff) was 99.2, 98, 100, and 74 % for stages I–IV, respectively.

Conclusion

A change in age cutoff in the AJCC/UICC staging for WDTC to 55 years would improve the accuracy of the system and appropriately prevent low-risk patients being overstaged and overtreated.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–53.PubMed Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–53.PubMed
2.
go back to reference Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164(6):658–61.PubMedCrossRef Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164(6):658–61.PubMedCrossRef
3.
go back to reference Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83(5):1012–21.PubMedCrossRef Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83(5):1012–21.PubMedCrossRef
4.
go back to reference Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15(8):1033–41.PubMedCrossRef Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15(8):1033–41.PubMedCrossRef
5.
go back to reference Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139–48.PubMedCrossRef Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139–48.PubMedCrossRef
6.
go back to reference Randolph G. Surgery of the thyroid and parathyroid glands. 2nd ed. Philadelphia: Elsevier; 2013. Randolph G. Surgery of the thyroid and parathyroid glands. 2nd ed. Philadelphia: Elsevier; 2013.
7.
go back to reference Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1050–57; discussion 1057–1058.PubMed Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1050–57; discussion 1057–1058.PubMed
8.
go back to reference Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–74.PubMedCrossRef Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–74.PubMedCrossRef
9.
go back to reference Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
10.
go back to reference Nixon IJ, Ganly I, Patel SG, et al. Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg. 2012;10(10):618–23.PubMedCrossRef Nixon IJ, Ganly I, Patel SG, et al. Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg. 2012;10(10):618–23.PubMedCrossRef
11.
go back to reference Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216–21.PubMedCrossRef Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216–21.PubMedCrossRef
12.
go back to reference Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2012;147(2):221–26.PubMedCrossRef Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2012;147(2):221–26.PubMedCrossRef
13.
go back to reference Bischoff LA, Curry J, Ahmed I, Pribitkin E, Miller JL. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract. 2013;19(6):995–97.PubMedCrossRef Bischoff LA, Curry J, Ahmed I, Pribitkin E, Miller JL. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract. 2013;19(6):995–97.PubMedCrossRef
14.
go back to reference Urken ML, Mechanick JI, Sarlin J, Scherl S, Wenig BM. Pathologic reporting of lymph node metastases in differentiated thyroid cancer: a call to action for the College of American Pathologists. Endocr Pathol. 2014:25(3):214–8.PubMedCrossRef Urken ML, Mechanick JI, Sarlin J, Scherl S, Wenig BM. Pathologic reporting of lymph node metastases in differentiated thyroid cancer: a call to action for the College of American Pathologists. Endocr Pathol. 2014:25(3):214–8.PubMedCrossRef
15.
go back to reference Terris DJ, Snyder S, Carneiro-Pla D, et al. American thyroid association statement on outpatient thyroidectomy. Thyroid. 2013;23(10):1193–202.PubMedCrossRef Terris DJ, Snyder S, Carneiro-Pla D, et al. American thyroid association statement on outpatient thyroidectomy. Thyroid. 2013;23(10):1193–202.PubMedCrossRef
16.
go back to reference Urken ML, Milas M, Randolph GW, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. Head Neck. 2015;37(4):605–14.PubMedCrossRef Urken ML, Milas M, Randolph GW, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. Head Neck. 2015;37(4):605–14.PubMedCrossRef
17.
go back to reference Shah JP. Re: Extent of surgery affects papillary thyroid cancer. Ann Surg. 2008;247(6):1082–83; author reply 1083–1084.PubMedCrossRef Shah JP. Re: Extent of surgery affects papillary thyroid cancer. Ann Surg. 2008;247(6):1082–83; author reply 1083–1084.PubMedCrossRef
Metadata
Title
Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer
Authors
Iain J. Nixon, PhD
Deborah Kuk, ScM
Volkert Wreesmann, PhD
Luc Morris, MD
Frank L. Palmer, BA
Ian Ganly, PhD
Snehal G. Patel, MD
Bhuvanesh Singh, MD
R. Michael Tuttle, MD
Ashok R. Shaha, MD
Mithat Gönen, PhD
Jatin P. Shah, PhD
Publication date
01-02-2016
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4762-2

Other articles of this Issue 2/2016

Annals of Surgical Oncology 2/2016 Go to the issue